ROXI-EVEREST
A Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention with REGN7508, a Monoclonal Antibody Against FXI, Versus Apixaban in Participants with Atrial Fibrillation (ROXI-EVEREST)
- Stadium
- pijplijn
- Middel
- REGN7508
- Populatie
- Ritme
- Fase
- III
- First Patient In
- 1 juli 2026
- Last Patient In
- 1 augustus 2028
- Last Patient Last Visit
- -
Contact Bestuur
